Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

• Published in: Cytotherapy (Oxford, England) England), 2014-06, Vol.16 (6), p.750-763
• Main Authors: Castiglia, Sara, Mareschi, Katia, Labanca, Luciana, Lucania, Graziella, Leone, Marco, Sanavio, Fiorella, Castello, Laura, Rustichelli, Deborah, Signorino, Elena, Gunetti, Monica, Bergallo, Massimiliano, Bordiga, Anna Maria, Ferrero, Ivana, Fagioli, Franca
• Format: Article
• Language: English
• Subjects: Advanced Basic Science; Animals; Blood Platelets - cytology; Cattle; Cell Culture Techniques; Cell Differentiation - genetics; Cell Extracts; Cell Proliferation - genetics; Good Manufacturing Practice; human platelet lysate; Humans; Immunophenotyping; inactivation; Mesenchymal Stem Cells - cytology; mesenchymal stromal cells; Other; psoralen
• ISSN: 1465-3249; 1477-2566
• DOI: 10.1016/j.jcyt.2013.12.008

Abstract Background aims Mesenchymal stromal cells (MSC) are ideal candidates for regenerative and immunomodulatory therapies. The use of xenogeneic protein–free Good Manufacturing Practice–compliant growth media is a prerequisite for clinical MSC isolation and expansion. Human platelet lysate (HPL) has been efficiently implemented into MSC clinical manufacturing as a substitute for fetal bovine serum (FBS). Because the use of human-derived blood materials alleviates immunologic risks but not the transmission of blood-borne viruses, the aim of our study was to test an even safer alternative than HPL to FBS: HPL subjected to pathogen inactivation by psoralen (iHPL). Methods Bone marrow samples were plated and expanded in α-minimum essential medium with 10% of three culture supplements: HPL, iHPL and FBS, at the same time. MSC morphology, growth and immunophenotype were analyzed at each passage. Karyotype, tumorigenicity and sterility were analyzed at the third passage. Statistical analyses were performed. Results The MSCs cultivated in the three different culture conditions showed no significant differences in terms of fibroblast colony-forming unit number, immunophenotype or in their multipotent capacity. Conversely, the HPL/iHPL-MSCs were smaller, more numerous, had a higher proliferative potential and showed a higher Oct-3/4 and NANOG protein expression than did FBS-MSCs. Although HPL/iHPL-MSCs exhibit characteristics that may be attributable to a higher primitive stemness than FBS-MSCs, no tumorigenic mutations or karyotype modifications were observed. Conclusions We demonstrated that iHPL is safer than HPL and represents a good, Good Manufacturing Practice–compliant alternative to FBS for MSC clinical production that is even more advantageous in terms of cellular growth and stemness.